Quoin CFO buys 10,244 ADSs plus 5,122 warrants
Lawlor also bought 5,122 ordinary warrants exercisable at $6.10 per ADS, immediately but subject to a beneficial ownership cap and expiring within five years.
Rhea-AI Filing Summary
Quoin Pharmaceuticals, Ltd. (QNRX) reported that Chief Financial Officer Sally Bridget Lawlor purchased 10,244 ADSs on August 31, 2026 at $4.88 per ADS in a private placement that included 50% warrant coverage. She also acquired 5,122 ordinary warrants exercisable at $6.10 per ADS, which became exercisable immediately subject to a beneficial ownership cap and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following these purchases, she directly owned 10,684 ADSs and 5,122 warrants.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 15,366 shares
Net Buy
2 txns
Insider
Lawlor Sally Bridget
Role
Chief Financial Officer
Bought
15,366 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Warrants (Right to Buy) F2, F3, F4, F1 | 5,122 | -- | -- |
| Purchase | ADSs F1, F2 | 10,244 | $4.88 | $50K |
Holdings After Transaction:
Ordinary Warrants (Right to Buy) — 5,122 contracts (Direct);
ADSs — 10,684 shares (Direct)
Footnotes (4)
- F1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2. Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
- F3. The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- F4. The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
Key Figures
ADSs purchased: 10,244 ADSs
Purchase price per ADS (combined with warrants): $4.88 per ADS
Warrants acquired: 5,122 ordinary warrants
+4 more
7 metrics
ADSs purchased
10,244 ADSs
Purchased by CFO on August 31, 2026 in private placement
Purchase price per ADS (combined with warrants)
$4.88 per ADS
Combined purchase price for ADSs and accompanying ordinary warrants
Warrants acquired
5,122 ordinary warrants
Right to buy ADSs acquired on August 31, 2026
Warrant exercise price
$6.10 per ADS
Exercise price for ordinary warrants acquired by CFO
ADS holdings after transaction
10,684 ADSs
Directly held by CFO following reported purchases
ADS to ordinary share ratio
35 ordinary shares per ADS
Each ADS represents thirty-five ordinary shares of Quoin
Net shares bought (ADSs and underlying warrants)
15,366 shares
Total shares associated with purchases in the Form 4 transaction summary
Key Terms
American Depositary Shares ("ADSs"), private placement, beneficial ownership cap, primary endpoint, +1 more
5 terms
private placement financial
"Purchased in Issuer's private placement of ADSs with 50% warrant coverage."
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
beneficial ownership cap financial
"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
primary endpoint medical
"30 days after the Issuer's public announcement that the primary endpoint has been met"
The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.
clinical trial CL-QRX003-004 medical
"in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome."
FAQ
What insider transactions did QNRX report for CFO Sally Bridget Lawlor?
Sally Bridget Lawlor purchased 10,244 ADSs at $4.88 per ADS and 5,122 ordinary warrants with a $6.10 exercise price per ADS on August 31, 2026 in a private placement with 50% warrant coverage.
How many QNRX ADSs does the CFO hold after the reported Form 4 transactions?
After the reported transactions, Chief Financial Officer Sally Bridget Lawlor directly held 10,684 ADSs of Quoin Pharmaceuticals, Ltd., according to the Form 4 disclosure.
What are the key terms of the QNRX warrants acquired by the CFO?
The CFO acquired 5,122 ordinary warrants, each exercisable for one ADS at an exercise price of $6.10 per ADS. The warrants were exercisable immediately, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after a specified trial endpoint announcement.
At what price were QNRX ADSs and warrants sold in the private placement?
The ADSs and accompanying ordinary warrants were issued at a combined purchase price of $4.88. The Form 4 states this combined price for the private placement of ADSs with 50% warrant coverage to the CFO.
What condition could shorten the life of the QNRX warrants acquired by the CFO?
The warrants will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
AI-generated analysis. How Rhea-AI works. Not financial advice.
